NCT07006480 Inpatient Use of Personal Continuous Glucose Monitor (CGM) to Improve Diabetes Mellitus Control
| NCT ID | NCT07006480 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Diabetes Mellitus |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2026-06-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2025-10-01 with a primary completion date of 2026-06-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research is to prove that data generated by your real-time personal continuous glucose monitors CGMs brought in the hospital at the time of hospitalization can be monitored and safely used to guide insulin therapy aiming to improve glycemic control and to diminish the hypoglycemia and hyperglycemia episodes without negatively affecting patients' satisfaction, providers and your nurses satisfaction with how glucose is monitored and treated in the hospital.
Eligibility Criteria
Inclusion Criteria: 1. Patients with ages above 18 years old at the time of informed consent. 2. Male or female 3. Admitted to non-ICU setting in brick-and-mortar medical and surgical ward or admitted to Advanced Care at Home Program. 4. Admitted under observation or inpatient status. 5. Expected to remain in the hospital for more than 48 hours. 6. Patients that are using a transcutaneous or implantable real time CGM as outpatient and are bringing it to the hospital. 7. Patients with diagnosis of diabetes mellitus or hyperglycemia requiring treatment with SQ insulin in the hospital either with multiple daily injections or subcutaneous infusion of insulin via insulin pump. Exclusion Criteria: 1. Participants unable to provide informed medical consent. 2. Participants admitted to Intensive Care Units (ICU). Enrollment is possible after transferring out of the ICU. 3. Actively being treated for DKA (diabetes ketoacidosis) or HHS (hyperosmolar hyperglycemic state) 4. Patients with a diagnosis of liver cirrhosis. 5. Patients with a diagnosis of ESRD or Acute Renal Failure on hemodialysis or peritoneal dialysis. 6. Patients with planned MRI or surgical procedure. Enrollment is possible after MRI or surgery. 7. Participants with allergy to medical grade adhesive or medical tape. 8. Participants who are pregnant, wanting to become pregnant, or nursing during study period. 9. Participants using Medtronic and Dexcom sensors and taking acetaminophen more than 4g per day or more than 1gm every 6 hours. 10. Participants using Dexcom sensors and taking hydroxyurea. 11. Participants using Libre sensors and taking over 500 mg of ascorbic acid. 12. Patients using Eversense sensors and taking tetracycline type of antibiotics. 13. Participants actively enrolled in other studies addressing their CGM use unless express permission is obtained from prior study research team principal investigator or co-principal investigator.
Contact & Investigator
Adrian G Dumitrascu, MD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT07006480 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07006480 currently recruiting?
Yes, NCT07006480 is actively recruiting participants. Contact the research team at dumitrascu.adrian@mayo.edu for enrollment information.
Where is the NCT07006480 trial being conducted?
This trial is being conducted at Jacksonville, United States.
Who is sponsoring the NCT07006480 clinical trial?
NCT07006480 is sponsored by Mayo Clinic. The principal investigator is Adrian G Dumitrascu, MD at Mayo Clinic. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.